Kamada Shares Rise

Kamada shares were higher 9% in early trade Friday after the company and Kedrion Biopharma said that Kedrab has obtained U.S. Food and Drug Administration approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal. Kedrab should be administered concurrently with a full course of rabies vaccine.

Rabies is a life-threatening condition that impacts 40,000 people in the U.S. each year, representing an annual market opportunity of $100 million-plus. Kedrab will launch in the U.S. in early 2018. Prior to FDA approval of Kedrab, U.S. healthcare professionals had only two human rabies immune globulin (HRIG) therapy options from which to choose to prevent the onset of rabies in someone who may have been exposed to the deadly virus.

Leave a Comment